ZBIO Zenas BioPharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1953926 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-185.3%
TTM EPS YoY-173.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-265.1%
ROA-108.7%
ROIC (approx.)-441.5%
Asset turnover—
Leverage & solvency
Liabilities / assets68.6%
Debt / equity0.00x
Current ratio9.42x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.45x
Accruals ratio-60.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $10.00M | $1.00M | — | $0 | $0 | $0 | $10.00M | $5.00M |
| R&D expense | $58.47M | $62.91M | $60.44M | $55.72M | $34.40M | $43.03M | $34.91M | $49.16M |
| SG&A expense | $27.43M | $15.75M | $16.91M | $15.59M | $13.18M | $12.14M | $12.41M | $11.47M |
| Operating income | -$103.41M | -$107.66M | -$77.35M | -$237.98M | -$52.58M | -$55.16M | -$37.33M | -$55.62M |
| Interest expense | $2.06M | $1.72M | $368,000 | — | — | — | — | — |
| Pretax income | -$108.87M | -$111.34M | -$80.99M | -$240.34M | -$51.50M | -$52.20M | -$33.78M | -$52.17M |
| Income tax | $49,000 | $114,000 | — | $106,000 | $0 | $20,000 | -$205,000 | — |
| Net income | -$108.92M | -$111.46M | -$80.99M | -$240.44M | -$51.50M | -$52.22M | -$33.57M | -$52.60M |
| EBITDA | -$103.41M | -$107.66M | -$77.34M | -$237.97M | -$52.57M | -$55.15M | -$37.31M | -$55.59M |
| EPS (basic) | -1.65 | -1.77 | -1.46 | — | -1.22 | -1.25 | -0.80 | — |
| EPS (diluted) | -1.65 | -1.77 | -1.46 | — | -1.22 | -1.25 | -0.80 | — |
| Weighted avg. shares (diluted) | 66.15M | 63.11M | 55.62M | — | 42.16M | 41.87M | 41.80M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $177.78M | $196.58M | $500.22M | $110.64M | $115.56M | $44.01M | $196.55M | $319.83M |
| Short-term investments | $407.53M | $446.55M | $216.98M | $232.55M | $175.32M | $229.27M | $115.83M | $31.02M |
| Current assets | $603.45M | $653.79M | $730.16M | $351.17M | $296.64M | $278.60M | $317.81M | $355.92M |
| PP&E, net | $19,000 | $23,000 | $28,000 | $34,000 | $50,000 | $61,000 | $72,000 | $185,000 |
| Total assets | $675.22M | $701.69M | $747.68M | $383.64M | $322.02M | $293.08M | $333.77M | $369.97M |
| Current liabilities | $64.04M | $65.82M | $61.16M | $62.65M | $52.42M | $53.24M | $49.13M | $57.29M |
| Long-term debt | — | — | — | $78.64M | $72.99M | — | — | — |
| Total debt | — | — | — | $78.64M | $72.99M | — | — | — |
| Total liabilities | $462.91M | $454.59M | $411.85M | $141.50M | $125.59M | $53.46M | $49.45M | $57.51M |
| Shareholders' equity | $212.31M | $247.10M | $335.83M | $242.14M | $196.43M | $239.63M | $284.32M | $312.46M |
| Net debt | — | — | — | -$32.01M | -$42.58M | — | — | — |
| Shares outstanding | 67.80M | 63.33M | 62.38M | 54.49M | 42.21M | 42.09M | 41.82M | 41.79M |
| Cash flow statement | ||||||||
| Operating cash flow | -$57.98M | -$57.24M | -$75.20M | -$52.41M | -$41.12M | -$41.74M | -$37.05M | -$38.55M |
| Capital expenditure | $1,000 | $0 | $2,000 | $0 | $0 | $0 | $18,000 | $74,000 |
| Free cash flow | -$57.98M | -$57.24M | -$75.20M | -$52.41M | -$41.12M | -$41.74M | -$37.07M | -$38.63M |
| Investing cash flow | -$19.21M | -$287.70M | $31.61M | -$93.36M | $40.04M | -$112.29M | -$86.27M | -$3.73M |
| Financing cash flow | $57.21M | $42.06M | $433.48M | $140.84M | $72.62M | $1.72M | $99,000 | $1.85M |
| Depreciation & amortization | $4,000 | $4,000 | $6,000 | $10,000 | $11,000 | $12,000 | $23,000 | $33,000 |
| Stock-based compensation | $17.28M | $8.62M | $9.20M | $7.58M | $7.34M | $6.04M | $5.39M | $5.50M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.